A
Andreas Orfanos
Researcher at Montreal Heart Institute
Publications - 5
Citations - 1870
Andreas Orfanos is an academic researcher from Montreal Heart Institute. The author has contributed to research in topics: Placebo & Randomized controlled trial. The author has an hindex of 5, co-authored 5 publications receiving 917 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction
Jean-Claude Tardif,Simon Kouz,David D. Waters,Olivier F. Bertrand,Rafael Diaz,Aldo P. Maggioni,Fausto J. Pinto,Reda Ibrahim,Habib Gamra,Ghassan S. Kiwan,Colin Berry,José López-Sendón,Petr Ostadal,Wolfgang Koenig,Denis Angoulvant,Jean Grégoire,Marc-André Lavoie,Marie-Pierre Dubé,David Rhainds,Mylène Provencher,Lucie Blondeau,Andreas Orfanos,Philippe L. L’Allier,Marie-Claude Guertin,François Roubille +24 more
TL;DR: Among patients with a recent myocardial infarction, colchicine at a dose of 0.5 mg daily led to a significantly lower risk of ischemic cardiovascular events than placebo.
Journal ArticleDOI
Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial.
Jean-Claude Tardif,Nadia Bouabdallaoui,Philippe L. L’Allier,Daniel Gaudet,Binita Shah,Michael H. Pillinger,Jose Lopez-Sendon,Protasio da Luz,Lucie Verret,Sylvia Audet,Jocelyn Dupuis,André Y. Denault,Martin Pelletier,Philippe A. Tessier,Sarah Samson,Denis Fortin,J.C. Tardif,David Busseuil,Elisabeth Goulet,Chantal Lacoste,Anick Dubois,Avni Y. Joshi,David D. Waters,Priscilla Y. Hsue,Norman E. Lepor,Frédéric Lesage,Nicolas Sainturet,Eve Roy-Clavel,Zohar Bassevitch,Andreas Orfanos,Gabriela Stamatescu,Jean Grégoire,Lambert Busque,Christian Lavallée,Pierre-Olivier Hétu,Jean-Sébastien Paquette,Spyridon Deftereos,Sylvie Levesque,Mariève Cossette,Anna Nozza,Malorie Chabot-Blanchet,Marie-Pierre Dubé,Marie-Claude Guertin,Guy Boivin +43 more
TL;DR: The COLCORONA trial as mentioned in this paper investigated the effect of colchicine on the composite of COVID-19-related death or hospital admission and found that colchics led to a lower rate of the composite adverse events than placebo.
Journal ArticleDOI
Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
Nadia Bouabdallaoui,Jean-Claude Tardif,David D. Waters,Fausto J. Pinto,Aldo P. Maggioni,Rafael Diaz,Colin Berry,Wolfgang Koenig,Wolfgang Koenig,Jose Lopez-Sendon,Habib Gamra,Ghassan S. Kiwan,Lucie Blondeau,Andreas Orfanos,Reda Ibrahim,Jean Grégoire,Marie-Pierre Dubé,Michelle Samuel,Olivier Morel,Olivier Morel,Pascal Lim,Olivier F. Bertrand,Simon Kouz,Marie-Claude Guertin,Philippe L. L’Allier,François Roubille +25 more
TL;DR: Patients benefit from early, in-hospital initiation of colchicine after MI, as well as for urgent hospitalization for angina requiring revascularization and the composite of cardiovascular death, resuscitated cardiac arrest, MI, or stroke.
Posted ContentDOI
Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19
Jean-Claude Tardif,Nadia Bouabdallaoui,Philippe L. L’Allier,Daniel Gaudet,Binita Shah,Michael H. Pillinger,Jose Lopez-Sendon,Protasio da Luz,Lucie Verret,Sylvia Audet,Jocelyn Dupuis,André Y. Denault,Martin Pelletier,Philippe A. Tessier,Sarah Samson,Denis Fortin,J.C. Tardif,David Busseuil,Elisabeth Goulet,Chantal Lacoste,Anick Dubois,Avni Y. Joshi,David D. Waters,Priscilla Y. Hsue,Norman E. Lepor,Frédéric Lesage,Nicolas Sainturet,Eve Roy-Clavel,Zohar Bassevitch,Andreas Orfanos,Jean Grégoire,Lambert Busque,Christian Lavallée,Pierre-Olivier Hétu,Jean-Sébastien Paquette,Sylvie Levesque,Mariève Cossette,Anna Nozza,Malorie Chabot-Blanchet,Marie-Pierre Dubé,Marie-Claude Guertin,Guy Boivin +41 more
TL;DR: A randomized, double-blind trial involving non-hospitalized patients with COVID-19 diagnosed by polymerase chain reaction (PCR) testing or clinical criteria was performed in this article.
Journal ArticleDOI
Cost-Effectiveness of Low-Dose Colchicine after Myocardial Infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)
Michelle Samuel,Jean-Claude Tardif,Paul Khairy,François Roubille,David D. Waters,Jean Grégoire,Fausto J. Pinto,Aldo P. Maggioni,Rafael Diaz,Colin Berry,Wolfgang Koenig,Petr Ostadal,Jose Lopez-Sendon,Habib Gamra,Ghassan S. Kiwan,Marie-Pierre Dubé,Mylène Provencher,Andreas Orfanos,Lucie Blondeau,Simon Kouz,Philippe L. L’Allier,Reda Ibrahim,Nadia Bouabdallaoui,Dominic Mitchell,Marie-Claude Guertin,Jacques LeLorier,Jacques LeLorier +26 more
TL;DR: Cost-effectiveness analyses indicate that the addition of colchicine to standard-of-care therapy after myocardial infarction is economically dominant and therefore generates cost savings.